CCR5 and skin cancer: The corresponding FDA-approved drugs include maraviroc (an antiretroviral drug, a CCR5 inhibitor), bosentan (a dual endothelin receptor antagonist that affects both endothelin A and B receptors, used in the treatment of pulmonary artery hypertension), sitaxentan (endothelin A receptor antagonist, used in the treatment of pulmonary artery hypertension), cetuximab (EGFR antagonist, used in several types of cancer) and imiquimod (an immune response modulator, used for skin diseases including skin cancer).